Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Other Accumulated Expenses (2016 - 2023)

Historic Other Accumulated Expenses for Editas Medicine (EDIT) over the last 9 years, with Q2 2023 value amounting to $78000.0.

  • Editas Medicine's Other Accumulated Expenses fell 9717.6% to $78000.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $78000.0, marking a year-over-year decrease of 9717.6%. This contributed to the annual value of $1.6 million for FY2022, which is 1612.22% up from last year.
  • Editas Medicine's Other Accumulated Expenses amounted to $78000.0 in Q2 2023, which was down 9717.6% from $109000.0 recorded in Q1 2023.
  • Over the past 5 years, Editas Medicine's Other Accumulated Expenses peaked at $4.0 million during Q2 2020, and registered a low of $78000.0 during Q2 2023.
  • In the last 5 years, Editas Medicine's Other Accumulated Expenses had a median value of $1.3 million in 2020 and averaged $1.5 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first soared by 28983.54% in 2020, then tumbled by 9717.6% in 2023.
  • Quarter analysis of 5 years shows Editas Medicine's Other Accumulated Expenses stood at $2.7 million in 2019, then tumbled by 57.87% to $1.1 million in 2020, then rose by 24.6% to $1.4 million in 2021, then rose by 16.12% to $1.6 million in 2022, then tumbled by 95.23% to $78000.0 in 2023.
  • Its Other Accumulated Expenses stands at $78000.0 for Q2 2023, versus $109000.0 for Q1 2023 and $1.6 million for Q4 2022.